ERBB2 and ovarian carcinoma: Treatment with agents directed against these proteins may enhance chemotherapy-induced cell death (Ciardiello et al, 2000; Altomare et al, 2004; Qiu et al, 2005; Lee et al, 2005b) The prognostic significance of EGFR and HER-2/neu has been extensively studied in ovarian cancer, but remains unclear.